The role of dopamine in regulating neuropsychiatric symptoms in alzheimer's disease - alzheimer's disease (ad) is the leading cause of dementia
Active Grant Awarded
- Award ID
- R21AG100982
- Recipient
-
Rutgers The State University Of New Jersey UEI YVVTQD8CJC79
- Awarding agency
-
National Institute on Aging
National Institutes of Health, Department of Health and Human Services
- Obligated
- $425,971
Award facts
- Assistance listing
- 93.866 Aging Research
- Completion date 10% complete
- Place of performance
- Newark, NJ 07107, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services, National Institutes of Health, National Institute on Aging awarded Rutgers The State University Of New Jersey $425,971 on September 9, 2026, under Assistance Listing 93.866, Aging Research, as grant R21AG100982. The award funds research investigating whether striatal dopamine underlies neuropsychiatric symptoms in Alzheimer's disease, including apathy, depression, anxiety, agitation, and psychosis. The work examines whether insulin signaling, which the source describes as fine-tuning striatal dopamine release, and brain insulin resistance affect dopamine function in Alzheimer's disease. The narrative also addresses APOE genetic variation, which the source links to brain insulin resistance. The awardee, doing business as RBHS-School of Nursing, performs the work in Newark, New Jersey (ZIP 07107). The period of performance runs from the September 9, 2026 award date to August 30, 2028. The assistance type is grant. The parent program supports biomedical, social, and behavioral research on the aging process and related diseases, with a particular emphasis on preventing and treating Alzheimer's disease and related dementias.
Description
Ad is predominantly known for its progressive cognitive impairment but also has an underrecognized neuropsychiatric component, which has profound clinical effects. Neuropsychiatric symptoms can include apathy, depression, anxiety, agitation, and even psychosis. Neuropsychiatric symptoms in ad often emerge before cognitive decline, suggesting they may arise from mechanisms distinct from those underlying cognitive impairment. Despite the significant impact of the neuropsychiatric symptoms, our understanding of the neuronal changes driving the neuropsychiatric manifestations in ad is limited. Each of the ad neuropsychiatric symptoms - apathy, depression, anxiety, agitation, and psychosis - are independently linked to dopamine function in the striatum, a brain region implicated in reward, motivation, and movement. This striking commonality in pathophysiology points to changes in dopamine function as a common unifying mechanism for ad-associated neuropsychiatric pathologies. This leads to a central question: does striatal dopamine underlie neuropsychiatric dysfunction in ad? A potential clue to the answer comes from a critical regulator of DA signaling, insulin. Brain insulin resistance is a key feature of ad and impaired insulin signaling in the brain has been shown to negatively affect both cognition and mood. New research from our laboratory, and others, has shown that insulin signaling can fine-tune dopamine release in the striatum. This provides a candidate mechanism by which insulin resistance might be affecting striatal dopamine function in ad. Genetic variation in apolipoprotein E (APOE), known to be the strongest genetic risk factor for late-onset ad, codes for a protein that facilitates the delivery of cholesterol to neurons and has been directly linked to insulin resistance in the brain. Emerging data suggest that APOE4 carriers are not only more prone to development of ad, but also the associated comorbid neuropsychiatric symptoms. This provides US with a perfect opportunity to employ the APOE genetic mouse model of ad to identify neural changes in striatal dopamine function and understand their contribution to neuropsychiatric symptoms. In the current proposal, we will investigate the central hypothesis that the ad-associated APOE4 variant impairs insulin receptor signaling leading to the depletion of dopamine function and development of neuropsychiatric symptoms observed in ad. Using a mouse model of human APOE4, we will identify (aim 1) how APOE genotype impacts the release of striatal dopamine in response to insulin and (aim 2) test the ability of insulin repletion to prevent the neuropsychiatric symptoms associated with ad. This research will reveal novel therapeutic pathways and management strategies for the often-overlooked neuropsychiatric symptoms exacerbated with APOE4-linked late-onset ad.
Quick answers
Who received award R21AG100982?
R21AG100982 was awarded to Rutgers The State University Of New Jersey by National Institute on Aging (National Institutes of Health) on September 9, 2026.
How much is award R21AG100982 worth?
$425,971 has been obligated on R21AG100982.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award